Corcept Therapeutics Incorporated
CORT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.62 | 0.74 | -4.25 | -1.21 |
| FCF Yield | 0.63% | 0.57% | 0.04% | 1.13% |
| EV / EBITDA | 539.88 | 277.98 | 3,044.87 | 198.35 |
| Quality | ||||
| ROIC | 1.11% | 4.50% | 1.04% | 3.47% |
| Gross Margin | 97.79% | 98.23% | 98.47% | 98.37% |
| Cash Conversion Ratio | 2.81 | 1.25 | 0.25 | 1.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.09% | 18.70% | 18.32% | 18.87% |
| Free Cash Flow Growth | 24.15% | 773.45% | -91.51% | -18.03% |
| Safety | ||||
| Net Debt / EBITDA | -7.56 | -3.54 | -21.40 | -4.69 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.37 | 0.28 | 0.17 | 0.24 |
| Cash Conversion Cycle | -402.53 | -265.02 | -473.19 | -63.54 |